Skip to content
Screener

LivaNova LIVN Q1 2025 earnings

Reported May 7, 2025 · Before market open

Revenue$316.9MMiss by $14.0M
EPS$0.88Beat by $0.13
Revenue estimate$330.9M
EPS estimate$0.75

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$381.1M
EPS estimate$1.04

Financials

Q1 2025

Income statement

See full
Revenue$316.9M+7.4%
Gross profit$216.3M+6.4%
Operating income$48.6M+199%
Net income-$327.3M-680%
EPS (diluted)-$6.01-671%

Balance sheet

See full
Cash & equivalents$738.4M+19.9%
Total debt$677.2M+0.2%
Total equity$1.0B-15.3%
Total assets$2.6B+4.0%

Cash flow

See full
Operating cash flow$24.0M+140%
CapEx$10.8M+68.6%
Free cash flow$13.2M+268%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.13B-29.3%
Enterprise value$2.07B-32.7%
P/S1.7×-0.9×

Profitability

See full
Gross margin67.9%+1.7pp
Operating margin12.7%+10.1pp
Net margin-17.4%-21.3pp
FCF margin11.4%+8.8pp

Returns & leverage

See full
Return on equity-19.7%-23.2pp
Debt / equity0.7×+0.1×
Current ratio1.6×-1.6×

Segments

By segment

See full
Cardiopulmonary$176.3M+13.1%
Neuromodulation$138.9M+3.8%

By geography

See full
Rest of World$88.0M+10.1%
Europe$59.7M+9.9%

FAQ

When did LivaNova report Q1 2025 earnings?
LivaNova (LIVN) reported Q1 2025 earnings on May 7, 2025 before market open.
What were LivaNova's Q1 2025 revenue and EPS?
LivaNova reported revenue of $316.9M and eps of $0.88 for Q1 2025.
Did LivaNova beat estimates in Q1 2025?
Revenue missed the consensus estimate of $330.9M by $14.0M. EPS beat the consensus estimate of $0.75 by $0.13.
How did LivaNova's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.4% from $294.9M a year earlier and eps grew 20.5% from $0.73.
Where can I find LivaNova's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001639691-25-000038) and the 10-Q periodic report (0001639691-25-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.